Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?

Wai-Tong Ng^{1

2}, Melvin L K Chua^{3

4

5}, Anne W M Lee^{1

2}

Affiliations

¹ Clinical Oncology Centre, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
³ Division of Radiation Oncology, Department of Head and Neck and Thoracic Cancers, National Cancer Centre Singapore, Singapore.
⁴ Division of Medical Sciences, National Cancer Centre Singapore, Singapore.
⁵ Oncology Academic Programme, Duke-NUS Medical School, Singapore.

Comment

Wai-Tong Ng et al. JAMA Oncol. 2022.

. 2022 Apr 1;8(4):524-525.

doi: 10.1001/jamaoncol.2021.7365.

Wai-Tong Ng^{1

2}, Melvin L K Chua^{3

4

5}, Anne W M Lee^{1

2}

¹ Clinical Oncology Centre, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
³ Division of Radiation Oncology, Department of Head and Neck and Thoracic Cancers, National Cancer Centre Singapore, Singapore.
⁴ Division of Medical Sciences, National Cancer Centre Singapore, Singapore.
⁵ Oncology Academic Programme, Duke-NUS Medical School, Singapore.

No abstract available

Comment on

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.
Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX, Xiang YQ. Liu GY, et al. JAMA Oncol. 2022 Apr 1;8(4):553-561. doi: 10.1001/jamaoncol.2021.7366. JAMA Oncol. 2022. PMID: 35175316 Free PMC article. Clinical Trial.